Biological Activities of a Novel Selective Oestrogen Receptor Modulator Derived from Raloxifene (Y134).
From: Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Zhangjiang High-tech Park, Pudong New District, Shanghai, China.
British journal of pharmacology
- Publish Date: Jan 2007
- ISSN: 0007-1188
- Volume: 150
- Issue: 1
- Pages: 19-28
- Medium: Print
- Language: English
- Citation (JAMA): Ning M, Zhou C, Weng J, et al. Biological Activities of a Novel Selective Oestrogen Receptor Modulator Derived from Raloxifene (Y134).. Br. J. Pharmacol. Jan 2007;150:19-28
Abstract
BACKGROUND AND PURPOSE: Selective oestrogen receptor (ER) modulators (SERMs) are of great value in the treatment of breast cancer and osteoporosis. The aim of this study was to characterize pharmacologically a new class of SERMs synthesized based on the core structure of raloxifene. EXPERIMENTAL APPROACH: Competitive receptor binding and luciferase-based reporter methods were used to study the bioactivities of raloxifene analogues, followed by efficacy determination in breast cancer cell proliferation assay. ER antagonist effects were investigated in female rats by measuring uterine and mammary gland growth, using wet weight, BrdU incorporation and terminal end bud (TEB) as indicators. KEY RESULTS: Five analogues, belonging to two different structural series and display higher binding affinities for ERalpha than ERbeta were functionally evaluated. One such analogue, Y134, exhibited potent antagonist activity at ERs in CV-1 cells cotransfected with plasmids containing ERalpha or ERbeta and oestrogen-response element-driven luciferase. The estimated IC(50) value was 0.52 nM for ERalpha and 2.94 nM for ERbeta, comparable to that of raloxifene. Little cytotoxicity was observed at Y134 concentrations below 10 microM. Y134 suppressed oestrogen-stimulated proliferation of ER-positive human breast cancer MCF-7 and T47D cells. At an identical dose, administered to ovariectomized rats, Y134 was more effective than raloxifene at arresting oestrogen-induced outgrowth of TEB and mammary gland DNA synthesis, but their inhibitory effects on the uterus were comparable. CONCLUSIONS AND IMPLICATIONS: Y134 is a potent ER antagonist with better mammary gland selectivity than raloxifene and shows potential for development as a new SERM for therapeutic use.
Mesh Headings (Keywords): Animals, Cell Line, Tumor, Female, Mammary Glands, Animal, Raloxifene, Rats, Rats, Sprague-Dawley, Receptors, Estrogen, Selective Estrogen Receptor Modulators, Transcription, Genetic, Uterus
Check for Full Text / PubMed Unique Identifier (PMID): 17115070
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.